Current opinion in immunologyHumansHematologic NeoplasmsGraft vs Leukemia EffectHematopoietic Stem Cell TransplantationKiller Cells
Optimizing post-transplantation cell therapies to enhance graft-versus-leukemia effects in hematological malignancies.
Simone A Minnie, Melissa M Berrien-Elliott, Melody Smith, Melinda A Biernacki, Marie Bleakley
Published: 202510.1016/j.coi.2025.102675
Abstract
Allogeneic hematopoietic cell transplantation (HCT) can cure patients with high-risk hematologic malignancies. Donor T and natural killer (NK) cells contribute to graft-versus-leukemia (GVL) effects that provide relapse protection. Post-HCT relapses…
Preview only. Read the full abstract at the source